We are happy to announce that Dr. Rahmo has been invited to present at the 6th Annual IPF (Idiopathic Pulmonary Fibrosis) Summit in Boston, August 29 – September 1. The subject of the approximately 45-minute presentation will focus on the intersection between COPD and IPF lung diseases. Specifically, how SMS cell therapy could eventually help with both indications based on the postulated and uncovered regenerative healing mechanism.
The IPF Summit’s focus is to guide pioneering drug sponsors and the wider biopharma community to develop successful disease-modifying IPF therapies, and advance the antifibrotic frontier. This is the only conference presenting scientific advancements as actionable insights for more innovative and clinically effective IPF drug development.
As new mechanisms, new approaches, and new targets come into the limelight, and innovations in translational modeling hit their stride to deliver in-human efficacy data; there has never been more translational or clinically relevant science for IPF than now.
